{"id":1172890,"date":"2020-03-20T14:20:50","date_gmt":"2020-03-20T20:20:50","guid":{"rendered":"https:\/\/www.mining.com\/?p=1017703"},"modified":"2020-03-20T14:20:50","modified_gmt":"2020-03-20T20:20:50","slug":"british-columbia-biotech-identifying-antibodies-for-covid-19","status":"publish","type":"post","link":"https:\/\/juniorminingnews.com\/?p=1172890","title":{"rendered":"British Columbia biotech identifying antibodies for Covid-19"},"content":{"rendered":"<p>A Vancouver biotech company that specializes in antibody discovery has partnered with American pharmaceutical company Eli Lilly and Co. (NYSE:LLY) to develop a new drug for the treatment and prevention of the COVID-19 virus.<\/p>\n<div class='d-flex justify-content-center d-xs-block d-sm-block d-md-none'>\n<div id='div-gpt-ad-1561499308230-0'><script>googletag.cmd.push(function() {googletag.display('div-gpt-ad-1561499308230-0');});<\/script><\/div>\n<\/div>\n<p>The private biotech developed what it calls a rapid pandemic response platform for the quick development, manufacturing and distribution of therapeutic antibodies.<\/p>\n<p>Eli Lilly will use AbCellera\u2019s platform to zero in on those antibodies that would prompt a natural immune response to the SARS-CoV-2 (COVID-19) virus, which is \u201cnovel\u201d \u2013 meaning humans do not have any natural immunity to it. The goal is to develop a new drug to treat people with the virus once they have it.<\/p>\n<figure class=\"wp-block-pullquote alignright\">\n<blockquote>\n<p>Within one week of&nbsp;receiving a blood sample of one of the first patients in the US to recover from the virus, AbCellera has identified 500 unique human antibody sequences<\/p>\n<\/blockquote>\n<\/figure>\n<p>The company states in a news release that, within one week of&nbsp;receiving a blood sample of one of the first patients in the US to recover from the virus, AbCellera has identified 500 unique human antibody sequences. <\/p>\n<p>\u201cThe next step is to screen these antibodies to find the ones most effective in neutralizing SARS-CoV-2,\u201d the company says in a news release.<\/p>\n<p>&#8220;AbCellera&#8217;s platform has delivered, with unprecedented speed, by far the world&#8217;s largest panel of anti-SAR-CoV-2 antibodies,&#8221; said AbCellera CEO Carl Hansen.<\/p>\n<p>&#8220;In 11 days, we&#8217;ve discovered hundreds of antibodies against the SARS-CoV-2 virus responsible for the current outbreak, moved into functional testing with global experts in virology, and signed a co-development agreement with one of the world&#8217;s leading biopharmaceutical companies.<\/p>\n<p>\u201cTogether, our teams are committed to delivering a countermeasure to stop the outbreak.&#8221;<\/p>\n<p>&#8220;We&#8217;ve partnered with AbCellera because we&#8217;re impressed with the speed and quality of their efforts,\u201d said Eli Lilly chief science officer Daniel Skovronsky.<\/p>\n<p>\u201cWe are moving at top speed to create a potential treatment to help patients. While typically a new therapeutic antibody program might take years to get in the clinic, our goal with AbCellera is to be testing potential new therapies in patients within the next four months.&#8221;<\/p>\n<p><em>(This article first appeared in <a href=\"https:\/\/biv.com\/\"  rel=\"noreferrer noopener\" aria-label=\"Business in Vancouver (opens in a new tab)\">Business in Vancouver<\/a>)<\/em><\/p>\n","protected":false},"excerpt":{"rendered":"<p>AbCellera, Eli Lilly hope to test new drug on Covid-19 patients within four months.<\/p>\n","protected":false},"author":47,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"site-sidebar-layout":"default","site-content-layout":"","ast-site-content-layout":"","site-content-style":"default","site-sidebar-style":"default","ast-global-header-display":"","ast-banner-title-visibility":"","ast-main-header-display":"","ast-hfb-above-header-display":"","ast-hfb-below-header-display":"","ast-hfb-mobile-header-display":"","site-post-title":"","ast-breadcrumbs-content":"","ast-featured-img":"","footer-sml-layout":"","theme-transparent-header-meta":"","adv-header-id-meta":"","stick-header-meta":"","header-above-stick-meta":"","header-main-stick-meta":"","header-below-stick-meta":"","astra-migrate-meta-layouts":"default","ast-page-background-enabled":"default","ast-page-background-meta":{"desktop":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"ast-content-background-meta":{"desktop":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"tablet":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""},"mobile":{"background-color":"var(--ast-global-color-5)","background-image":"","background-repeat":"repeat","background-position":"center center","background-size":"auto","background-attachment":"scroll","background-type":"","background-media":"","overlay-type":"","overlay-color":"","overlay-gradient":""}},"footnotes":""},"categories":[369,4],"tags":[],"_links":{"self":[{"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=\/wp\/v2\/posts\/1172890"}],"collection":[{"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=\/wp\/v2\/users\/47"}],"replies":[{"embeddable":true,"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=1172890"}],"version-history":[{"count":2,"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=\/wp\/v2\/posts\/1172890\/revisions"}],"predecessor-version":[{"id":1172896,"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=\/wp\/v2\/posts\/1172890\/revisions\/1172896"}],"wp:attachment":[{"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=1172890"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=1172890"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/juniorminingnews.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=1172890"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}